{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T20:31:45Z","timestamp":1768249905412,"version":"3.49.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.eplepsyres.2013.10.005","type":"journal-article","created":{"date-parts":[[2013,10,23]],"date-time":"2013-10-23T20:31:12Z","timestamp":1382560272000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Eslicarbazepine acetate: An update on efficacy and safety in epilepsy"],"prefix":"10.1016","volume":"108","author":[{"given":"Alberto","family":"Verrotti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Loiacono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Zaccara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0005","series-title":"Zebinix: EPAR\u2014Product Information","author":"Agency, European Medicines","year":"2009"},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0010","series-title":"The Treatment of Epilepsy","first-page":"485","article-title":"Eslicarbazepine acetate","author":"Almeida","year":"2009"},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0015","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1177\/0091270005279364","article-title":"Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects","volume":"45","author":"Almeida","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0020","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00228-007-0414-1","article-title":"Pharmaccokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment","volume":"64","author":"Almeida","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0025","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1177\/0091270008319706","article-title":"Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy","volume":"48","author":"Almeida","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0030","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1600-0404.2009.01233.x","article-title":"Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects","volume":"121","author":"Almeida","year":"2010","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0035","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.nurt.2006.10.005","article-title":"Eslicarbazepine acetate (BIA 2-093)","volume":"4","author":"Almeida","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0040","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0014-2999(00)00659-2","article-title":"Neurotoxic\/neuroprotective profile of carbamazepine, oxcarbazepine and two new putative antiepileptic drugs, BIA 2-093 and BIA 2-024","volume":"406","author":"Ambrosio","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0045","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0006-2952(01)00584-6","article-title":"Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivates of carbazepine, due to blockade of sodium but not calcium channels","volume":"61","author":"Ambrosio","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0050","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1021\/jm980627g","article-title":"Anticonvulsivant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz(b,f)azepine-5-carboxamide derivatives","volume":"42","author":"Benes","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0055","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eplepsyres.2010.01.014","article-title":"Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy","volume":"89","author":"Ben-Menachem","year":"2010","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2008.09.005","article-title":"Progress report on new antiepileptic drugs: a summary of the Ninth EILAT Conference (EILAT IX)","volume":"83","author":"Bialer","year":"2009","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0065","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1517\/13543784.15.6.637","article-title":"New antiepileptic drugs that are second generation to existing antiepilepting drugs","volume":"15","author":"Bialer","year":"2006","journal-title":"Expert. Opin. Invest. Drugs"},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0070","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrd2997","article-title":"Key factors in the discovery and development of new antiepileptic drugs","volume":"9","author":"Bialer","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0075","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1528-1157.2001.43600.x","article-title":"Interaction of the novel anticonvulsivant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine","volume":"42","author":"Bonifacio","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0080","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1136\/bmj.331.7528.1317","article-title":"Epilepsy in elderly people","volume":"331","author":"Brodie","year":"2005","journal-title":"Br. Med. J."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0085","first-page":"103","article-title":"Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures","volume":"6","author":"Brown","year":"2010","journal-title":"Ther. Clin. Risk Manage."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0090","first-page":"1","article-title":"Eslicarbazepine acetate add-on for drug-resistant partial epilepsy","volume":"12","author":"Chang","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0095","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1034\/j.1600-0773.2002.900407.x","article-title":"Effects of carbazepine and novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives on synaptic transmission in rat hippocampal slices","volume":"90","author":"Cunha","year":"2002","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0100","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1528-1167.2007.00984.x","article-title":"Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures","volume":"48","author":"Elger","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0105","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1528-1167.2008.01946.x","article-title":"Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group Phase 3 study","volume":"50","author":"Elger","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0110","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/epi.12242","article-title":"Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers","volume":"54","author":"Elger","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0115","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/mol.107.039867","article-title":"The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels","volume":"73","author":"Errington","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0120","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/bdd.549","article-title":"Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker","volume":"28","author":"Falc\u00e3o","year":"2007","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2013.04.009","article-title":"Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects","author":"Falc\u00e3o","year":"2013","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0130","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.eplepsyres.2013.02.020","article-title":"Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol\/levonorgestrel oral contraceptive in healthy women","volume":"105","author":"Falc\u00e3o","year":"2013","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0135","series-title":"The Treatment of Epilepsy","first-page":"575","article-title":"Oxcarbazepine","author":"Faught","year":"2009"},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0140","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1528-1167.2012.03605.x","article-title":"Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies","volume":"54","author":"Gil-Nagel","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0145","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0404.2009.01218.x","article-title":"Efficacy and safety of 800 and 1200mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures","volume":"120","author":"Gil-Nagel","year":"2009","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0150","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0920-1211(01)00231-5","article-title":"Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(\u2212)-10,11-dihydro-10-hydroxy carbamazepine","volume":"44","author":"Hainzl","year":"2001","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0155","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1111\/j.1528-1167.2010.02660.x","article-title":"Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy","volume":"51","author":"Halasz","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0160","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.eplepsyres.2012.07.014","article-title":"Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study","volume":"103","author":"Hufnagel","year":"2013","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0165","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1345\/aph.1G209","article-title":"Carbamazepine-induced hyponatremia: assessment of risk factors","volume":"39","author":"Kuz","year":"2005","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0170","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0175","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/seiz.2000.0442","article-title":"Epilepsy after the first drug fails: substitution or add-on?","volume":"9","author":"Kwan","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0180","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5414\/CPP46119","article-title":"Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate","volume":"46","author":"Maia","year":"2008","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0185","article-title":"Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: preliminary results","author":"Massot","year":"2013","journal-title":"Neurologia"},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0190","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJM199209103271104","article-title":"A comparison of valproate with carbamazepine for the treatment of partial seizures and secondarily generalised tonic\u2013clonic seizures in adults","volume":"327","author":"Mattson","year":"1992","journal-title":"N. Engl. J."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0195","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/0023210-200923010-00005","article-title":"Eslicarbazepine acetate","volume":"23","author":"McCormack","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0200","series-title":"The Treatment of Epilepsy: Principles and Practice","first-page":"1215","article-title":"Cognitive effects of epilepsy and of antiepileptic medications","author":"Meador","year":"2004"},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0205","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.yebeh.2010.04.022","article-title":"Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers","volume":"18","author":"Milovan","year":"2010","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0210","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/WNF.0b013e318271220b","article-title":"Eslicarbazepine acetate in the management of refractory bipolar disorder","volume":"35","author":"Nath","year":"2012","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0215","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1528-1167.2012.03595.x","article-title":"Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers","volume":"54","author":"Nunes","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0220","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0197-0186(01)00101-2","article-title":"The novel anticonvulsivant BIA 2-093 inhibits transmitter release during opening of voltage-gated sodium channels: a comparison with carbamazepine and oxcarbazepine","volume":"40","author":"Parada","year":"2002","journal-title":"Neaurochem. Int."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0225","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.eplepsyres.2011.05.013","article-title":"Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures","volume":"96","author":"Perucca","year":"2011","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0230","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1111\/j.1528-1157.2000.tb02175.x","article-title":"Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults","volume":"41","author":"Reife","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0235","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1528-1157.1984.tb03446.x","article-title":"Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects","volume":"25","author":"Riva","year":"1984","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0240","doi-asserted-by":"crossref","first-page":"255","DOI":"10.5414\/CPP47255","article-title":"Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects","volume":"47","author":"Rocha","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0245","series-title":"Antiepileptic Drugs","first-page":"3","article-title":"Priciples of antiepileptic drug action","author":"Rogawski","year":"2002"},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0250","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00019052-200304000-00008","article-title":"The epidemiology of epilepsy revisited","volume":"16","author":"Sander","year":"2003","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0255","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1006\/ebeh.2000.0126","article-title":"Oxcarbazepine for treatment of partial epilepsy: a review and recommendations for clinical use","volume":"1","author":"Schmidt","year":"2000","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0260","doi-asserted-by":"crossref","first-page":"309","DOI":"10.33588\/rn.5606.2013031","article-title":"Eslicarbazepine acetate in clinical practice. Efficacy and safety results","volume":"56","author":"Serrano-Castro","year":"2013","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0265","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1053\/seiz.2000.0391","article-title":"Oxcarbazepine: a review","volume":"9","author":"Sharvon","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0270","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.eplepsyres.2006.07.010","article-title":"Anticonvulsant effect of eslicarbazepine acetate (BIA 2-093) on seizures induced by microperfusion of picrotoxin in the hippocampus of freely moving rats","volume":"72","author":"Sierra-Paredes","year":"2006","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0275","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.eplepsyres.2007.08.006","article-title":"Effect of eslicarbazepine acetate (BIA 2-093) on latrunculin A-induced seizures and extracellular amino acid concentrations in the rat hippocampus","volume":"77","author":"Sierra-Paredes","year":"2007","journal-title":"Epilepsy Res."},{"issue":"Suppl. 8","key":"10.1016\/j.eplepsyres.2013.10.005_bib0280","first-page":"157","article-title":"BIA 2-093 pharmacokinetics in healthy elderly subjects","volume":"45","author":"Silveira","year":"2004","journal-title":"Epilepsia"},{"issue":"Suppl. 5","key":"10.1016\/j.eplepsyres.2013.10.005_bib0290","first-page":"1","article-title":"Slow and fast inactivator of voltage gated sodium channels by eslicarbazepin and carbazepine","volume":"53","author":"Soares-da-Silva","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0295","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.eplepsyres.2006.01.011","article-title":"Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy","volume":"69","author":"Striano","year":"2006","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0300","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2125.2007.02984.x","article-title":"Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets","volume":"65","author":"Tothfalusi","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0305","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1472-8206.2009.00691.x","article-title":"Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects","volume":"23","author":"Vaz-da-Silva","year":"2009","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0310","first-page":"191","article-title":"Eslicarbazepine acetate pharmacokinetics after single and repeated doses in healthy subjects","volume":"46","author":"Vaz-de-Silva","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0315","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2174\/138161206775474468","article-title":"Na+ channel pharmacology and molecular mechanisms of gating","volume":"12","author":"Yamaoka","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0320","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1528-1167.2007.01041.x","article-title":"Idiosyncratic adverse reactions to antiepileptic drugs","volume":"48","author":"Zaccara","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.10.005_bib0325","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.seizure.2013.03.016","article-title":"Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine","volume":"22","author":"Zaccara","year":"2013","journal-title":"Seizure"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121113002593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121113002593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:29:50Z","timestamp":1760275790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121113002593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0920121113002593"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2013.10.005","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eslicarbazepine acetate: An update on efficacy and safety in epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2013.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}